drugset
drugset / Trial / NCT05074810

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

NCT05074810 ↗

Phase 1/2 Active not recruiting 153 enrolled Verastem, Inc. Amgen · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.

Timeline

Start
2022-04-12
Primary completion
2026-06
Completion
2027-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Avutometinib Small molecule — —
Subject Defactinib Small molecule — —
Subject Sotorasib Small molecule — —

Indications

non-small cell lung carcinoma